Search

Displaying results 4671 - 4680 of 8010 in total
  1. Target

    Serine/threonine-protein kinase SIK1

    go.drugbank.com/bio_entities/BE0004757
    TargetHumans

    Also required during cardiomyogenesis by regulating the exit of cardiomyoblasts from the cell cycle via down-regulation of CDKN1C/p57Kip2. … Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: required for phosphorylation of p53/TP53 in response to loss of adhesion

    Synonyms: Salt-inducible kinase 1
  2. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    XenoPort in 2011 for the treatment of GERD. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  3. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a developed for the treatment of autoimmune diseases.

  4. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. … MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.

  5. Drug

    Phensuximide

    go.drugbank.com/drugs/DB00832
    Approved

    The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

  6. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

    Categories: Drugs for Functional Gastrointestinal Disorders
  7. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal beha...

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic

  9. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  10. Drug

    Indopan

    go.drugbank.com/drugs/DB01446
    ExperimentalIllicit

    It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates